A2 Biotherapeutics

A2 Biotherapeutics

Biotechnology, Agoura Rd Unit 210, Agoura Hills, , 91301, California, 30301, United States, 51-200 Employees

a2bio.com

  • facebook
  • LinkedIn

Who is A2 BIOTHERAPEUTICS

A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. A2 engineers T c...

Read More

map
  • 30301 Agoura Rd Unit 210, Agoura Hills, California, 91301, United States Headquarters: 30301 Agoura Rd Unit 210, Agoura Hills, California, 91301, United States
  • 2018 Date Founded: 2018
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731

checked-icon Does something look wrong? Fix it. | View contact records from A2 BIOTHERAPEUTICS

A2 Biotherapeutics Org Chart and Mapping

Employees

Julie Cavanaugh

Quality Control Associate Scientist

Talar Tokatlian

Principal Scientist, Drug Discovery

Gregory Nelson

Quality Control Associate Scientist, Microbiology

Chad Berube

Senior Manufacturing Associate

Brad Glick

Information Technology Manager

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding A2 Biotherapeutics

Answer: A2 Biotherapeutics's headquarters are located at Agoura Rd Unit 210, Agoura Hills, , 91301, California, 30301, United States

Answer: A2 Biotherapeutics's official website is https://a2bio.com

Answer: A2 Biotherapeutics's revenue is $1 Million to $5 Million

Answer: A2 Biotherapeutics's SIC: 8731

Answer: A2 Biotherapeutics has 51-200 employees

Answer: A2 Biotherapeutics is in Biotechnology

Answer: A2 Biotherapeutics contact info: Phone number: Website: https://a2bio.com

Answer: A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access